bluuebunny/crossref_metadata_2025_split huggingface dataset:
Salvage chemotherapy for non Hodgkin's lymphoma of unfavourable histology with a combination of ccnu and vinblastine
Authors: Palmieri G. , Lauria R. , Caponigro F. , Pagliarulo C. , Montesarchio V. , Nuzzo F. , Gridelli C. , Bianco A. R. 
Published: February 2007

AbstractTwenty patients with relapsed or refractory, intermediate or high grade non Hodgkin's lymphoma were treated with a combination of CCNU and vinblastine. Complete responses occurred in four patients (20 per cent), partial responses in eight (40 per cent), for an overall response rate of 60 per cent. The regimen was more effective in patients with high grade lymphoma, absence of constitutional symptoms, better response to prior treatment. Duration of response was 4, 8, 16, 30 months for complete responders; 2, 2, 6, 6, 6, 8, 9, 14 months for partial responders. This combination regimen seems at least as effective as most of other regimens utilized in salvage treatment of non Hodgkin's lymphomas, with a very acceptable toxicity.
Heterogeneous expression of proto‐oncogenes in Hodgkin's disease derived cell lines
Authors: Jücker M. , Schaadt M. , Diehl V. , Poppema S. , Jones D. , Tesch H. 
Published: February 2007

AbstractThe expression of 20 proto‐oncogenes was analysed by Northern blotting in four cell lines derived from patients with Hodgkin's disease (L428, L540, CO and DEV) and compared to lymphoid and myeloid leukemia cell lines and normal hematopoietic cells. Expression of the proto‐oncogenes c‐myc, p53, c‐jun, pim‐1, lck, c‐syn, c‐raf and N‐ras were detected in Hodgkin's disease derived cell lines and in normal hematopoietic cells. Transcripts of the proto‐oncogene c‐met were detected in the Hodgkin's derived cell lines L428 and L540 but not in the lymphoid or myeloid leukemia cell lines or in tonsil cells, peripheral blood mononuclear cells and granulocytes. Expression of the proto‐oncogenes N‐myc and lck were observed in the Hodgkin's derived cell line CO which express T cell receptor genes and in the T cell lines JM and CEM. L428 cells and CO cells expressed aberrant transcripts of the c‐fes proto‐oncogene. Thus Hodgkin's disease derived cell lines are heterogenous in their expression pattern of proto‐oncogenes, expressing normal and aberrant transcripts of proto‐oncogenes which are not found in untransformed hematopoietic cells.
Clinical features associated with transformation of cerebriform T‐cell lymphoma to a large cell process
Authors: Greer John P. , Salhany Kevin E. , Cousar John B. , Fields James P. , King Lloyd E. , Graber Stanley E. , Flexner John M. , Stein Richard S. , Collins Robert D. 
Published: February 2007

AbstractSome patients with cerebriform T‐cell lymphoma (CTCL) undergo morphologic transformation to a large cell lymphoma. From a series of 113 patients with CTCL, 22 patients were identified with transformed CTCL. Stages of involvement at diagnosis were: I (seven), II (four), III (four), IV (seven). Nine patients had transformation at the initial diagnosis while the median time from diagnosis to transformation in the other 13 patients was 16 months (range: 3 months–6 years). Thirteen had transformation extracutaneously: lymph nodes (eight), central nervous system (two), and other extranodal sites (three). T cell markers were identified in all cases; of 15 cases with complete phenotypes, there were eight T‐helper, three T‐suppressor, and four aberrant T phenotypes. Serology for human T‐leukemia virus‐I (HTLV‐I) was negative in eight patients tested. Median survival from diagnosis was 27 months compared to 53 months in 53 patients without transformation (p = 0.003). Despite combination chemotherapy in 12 patients following transformation, median survival after transformation was 12 months and only 7 months with extracutaneous disease. The likelihood of transformation could not be predicted by the initial histology, immunophenotype, or stage of disease.
Characterization of giant cells in Hodgkin's lymphomas by immunohistochemistry applied to randomly collected diagnostic biopsies from the german Hodgkin trial
Authors: Werner M. , Georgii A. , Bernhards J. , Hübner K. , Schwarze E. W. , Fischer R. 
Published: February 2007

AbstractA panel of 10 monoclonal antibodies reactive with formalin‐resistant epitopes was applied to characterize the giant cells of the Reed‐Sternberg, Hodgkin, and lacunar cell types in diagnostic biopsies from the German Hodgkin Trial. The 94 tissue samples examined had been sent to the Reference Center by 44 different laboratories which made the initial diagnoses. A board of four referees re‐classified the primary diagnoses established by the 44 different histopathologists, providing subtyping of Nodular Sclerosis according to Bennett et al. (1985, 1989). Only cases with unequivocal agreement among the referees and which satisfied standards of fixation and embedding were included. Giant cells stained positively with: Ber‐H2 in 92 per cent (81/88), LN‐2 in 86.4 per cent (76/88), and DAKO‐M1 in 72.2 per cent (64/88) of cases in which the lymphocyte predominance type was not included. Positive staining was quite rare with the other seven monoclonal antibodies. No significant difference in reactivity was revealed between giant cells of Reed‐Sternberg, lacunar or Hodgkin cell types. Approximately one third of the cases were negative for at least one of the markers, Ber‐H2, LN‐2 or DAKO‐M1. The lymphocytic and histiocytic cells in lymphocyte predominance Hodgkin's disease displayed a distinctive staining pattern with positivity for B‐cell markers, whereas DAKO‐M1 and Ber‐H2 were predominantly negative.Finally, we found that randomly collected blocks of primary biopsies permit reliable immunostaining by this panel of monoclonal antibodies, since our results agree with results from the literature obtained from biopsies processed according to more uniform protocols for fixation and embedding.
Necrotizing lymphadenitis: A review of clinicopathological, immunohistochemical and ultrastructural studies
Authors: Asano Shigeyuki , Akaike Yasushi , Jinnouchi Hirokazu , Muramatsu Takao , Wakasa Haruki 
Published: February 2007

AbstractNecrotizing lymphadenitis (NEL) has been reported to be a reactive process described under differing terminology by Fujimoto et al. (1972), Kikuchi (1972), Wakasa et al. (1973) and other Japanese pathologists. Recently, this type of lymphadenitis has also been reported in America and Europe.In Japan, NEL is observed more frequently in the northern area, however, no characteristic seasonal occurrence has been noted. The disease affects young females more than males, particularly from the third and fourth decades onwards. Common cold‐like symptoms, lymphadenopathy of the cervical region and leukopenia are characteristic clinical findings in the early stages.Morphological features of the involved lymph nodes include the presence of numerous immunoblasts, histiocytes and macrophages, the latter with phagocytized nuclear debris derived from degenerated lymphocytes. However, granulocytes are generally absent. Tubular inclusions are observed ultrastructurally.Immunohistochemical studies of peripheral blood using monoclonal antibodies have revealed that the helper/suppressor (Leu 3a/2a) ratio increases gradually with the clinical course because of a decrease in Leu 2a + cells. The pathogenesis of NEL is uncertain, but it has been speculated that there is cytolytic infection of lymphocytes by a virus or other organism, accompanied by secondary blastic transformation of suppressor T‐lymphocytes.
Hepatitis B infection in patients with lymphomas
Authors: Liang Raymond H. S. , Lok Anna S. F. , Lai C. L. , Chan T. K. , Todd David , Chiu Edmond K. W. 
Published: February 2007

AbstractThis paper reviewed the clinical characteristics and treatment outcome of 484 lymphoma patients with known hepatitis B status. Comparisons were made between the hepatitis B surface antigen positive and negative patients. Also, the effect of treatment for lymphomas, including cytotoxic chemotherapy, in the hepatitis B antigen positive patients were analysed. The hepatitis B status was determined in 484 Chinese lymphoma patients at the time of initial diagnosis. Hepatic complications occurring during therapy for lymphomas were analysed. Although our lymphoma patients had a similar prevalence of hepatitis B markers of 42 per cent, they had a strikingly higher positive rate of 22 per cent for hepatitis B surface antigen and a relatively lower positive rate of 20 per cent for antibody, as compared to the respective figures of 9.5 per cent and 33 per cent in the control population. The hepatitis B surface antigen positive patients were younger than the negative patients but their treatment outcomes were similar despite the higher incidence of hepatic complications (21 per cent) in the hepatitis B surface antigen positive patients during therapy for lymphomas. None of the clinical parameters analysed appeared to be useful in predicting the development of these complications which included fatal liver failure (5.7 per cent), icteric hepatitis (5.7 per cent) and anicteric hepatitis (9.5 per cent). The high prevalence of hepatitis B surface antigen in our lymphoma patients may be related to the immunosuppressive effect of lymphomas. There is no definite evidence to suggest that hepatitis B infection has an aetiological or promoting role in the pathogenesis of lymphomas. Hepatitis B infection has contributed to the high incidence of hepatic complications during therapy for lymphomas and possible ways of prevention need to be investigated.
The occurrence of variant Ph translocations in chronic myeloid leukemia (CML): A report of SIX cases
Authors: Kadam Pratibha R. , Nanjangud Gouri J. , Advani Suresh H. 
Published: February 2007

AbstractVariants of Philadelphia chromosome (Ph) translocation were detected in six of 95 Ph positive chronic myeloid leukemia (CML) patients (6·3 per cent). Two of these patients showed a Ph variant of ‘simple’ type, involving chromosomes 10 and 12. In four patients, the variant Ph was of ‘complex’ type involving a third chromosome:chromosomes 1, 6, 7 and 12 in addition to 9 and 22. Two of these resulted in the occurrence of a ‘masked’ Ph. In addition to variant Ph translocations, variant breakpoints such as q12 (two patients) and q13 (one patient) on chromosome 22 were observed in another three patients with t(9;22).
CAVBP/DEP alternating chemotherapy for the treatment of intermediate and high grade non Hodgkin's lymphoma: Final results of a pilot study
Authors: Palmieri Giovannella , Caponigro Francesco , Iaffaioli Rosario Vincenzo , Contegiacomo Alma , Montesarchio Vincenzo , Lauria Rossella , Calderopoli Rita , Pagliarulo Clorindo , Gridelli Cesare , Bianco Angelo Raffable 
Published: February 2007

AbstractBetween May 1984 and September 1986, 40 patients with intermediate or high grade non Hodgkin's lymphoma were treated with a novel protocol, which alternated a conventional regimen consisting of cyclophosphamide, doxorubicin, vincristine, bleomycin, and prednisone (CAVBP) with a second chemotherapy regimen, including two drugs with newly discovered activity against lymphomas, such as cis‐platin, etoposide, and prednisone (DEP). Twenty‐one patients (52.5 per cent) achieved a complete response, 11 patients (27.5 per cent) had a partial response. Eight of the 21 complete responders (38 per cent) relapsed 5 to 24 months after completion of treatment. With a median follow‐up of over 40 months, 22 patients are alive, six with disease and three in a second complete response after salvage chemotherapy. Factors negatively associated with response included ‘B’ symptoms, advanced stage of disease, bulky tumour, poor performance status, number of extranodal sites of disease. ‘B’ symptoms, bulky tumour, and poor performance status were also negatively associated with survival. Toxicity was modest, with no treatment‐related deaths and only six cases of severe leukopenia. The results of this pilot study do not justify comparison of CAVBP/DEP with more efficacious regimens in prospective, randomized trials.
Primary and secondary cutaneous lymphomas in Hong Kong Chinese
Authors: Liang Raymond , Chiu Edmond , Loke S. L. , Chan T. K. , Todd David , Ho Faith 
Published: February 2007

AbstractSixty‐eight Hong Kong Chinese patients with cutaneous lymphomas were studied. There were 38 males and 30 females and their median age was 52 years. According to a staging system as proposed by the Mycosis Fungoides Cooperative Group, 48 (71 per cent) of the patients had disseminated stage IV disease. There were nine (13 per cent) cases of mycosis fungoides. The remaining cases were mostly intermediate or high grade non‐Hodgkin's lymphomas according to the Working Formulation. Immunophenotyping was performed in 23 cases and in 17 cases (74 per cent), T‐cell tumours were identified. Many of these T‐cell lymphomas were unclassifiable according to the Working Formulation and were either pleomorphic or immunoblasticlymphadenopathy‐like T‐cell lymphoma according to a modified system of the Japanese Lymphoma Study Group. A variety of therapies were given to these patients and those with stage IV disease had a significantly poorer survival. On the other hand, the histology, and immunophenotype did not appear to be useful in predicting prognosis.
Flow cytometric analysis of DNA ploidy in large cleaved cell lymphomas
Authors: Aine Risto , Lehtinen Tuula , Lehtinen Matti , Blanco Guillermo , Apaja‐Sarkkinen Meeri , Leinikki Pauli , Alavaikko Martti 
Published: February 2007

AbstractThe results of nuclear DNA content analysis of a series of 28 patients with large cleaved follicular centre cell non‐Hodgkin's lymphomas (NHL) are reported. DNA aneuploidy was found in 11 (39 per cent) cases. The DNA indices of the DNA‐aneuploid peaks ranged from 1.14 to 2.28. Seven (25 per cent) cases were tetraploid. DNA ploidy was not associated with prognosis. The percentage of S phase cells (SPF) ranged from 2.0 to 30.5 per cent (median 5.1 per cent). Lymphoma patients with SPF higher than 9.7 per cent had a worse survival rate than patients with lymphoma with less than 9.7 per cent S phase cells but the difference did not reach statistical significance. The results of the DNA ploidy and SPF were comparable to those of intermediate and high grade malignancy NHLs.
Cytokine expression in B‐cell non‐Hodgkin lymphomas
Authors: Merz H. , Fliedner A. , Lehrnbecher Th. , Sebald W. , Müller‐Hermelink H. K. , Feller A. C. 
Published: February 2007

AbstractCytokine expression of potentially active B‐cell growth factors (IL‐2, IL‐4, IL‐6) was investigated by means of mRNA‐expression in 29 cases of malignant non‐Hodgkin B‐cell lymphomas. Strong signals were found for IL‐4 and IL‐6 in two and five cases, respectively, whereas the majority of the remaining cases did not show any detectable mRNA‐signals for these growth factors. Comparing these results with those of the immunohisto‐chemistry, it could be demonstrated that at least in some of these cases the signal was due to an autocrine or paracrine phenomenon of the tumour cells.
Specific chromosomal changes in patients with acute nonlymphocytic leukemia from India
Authors: Kadam P. R. , Merchant A. A. , Advani S. H. , Nair C. 
Published: February 2007

AbstractWe analysed forty consecutive patients with acute nonlymphocytic leukemia (ANLL) using methotrexate cell synchronization and 24 h‐unstimulated cultures of bone marrow cells to determine the incidence of chromosomal aberrations and the association of specific anomalies with FAB morphological subtypes, in an Indian population. All patients demonstrated an abnormal karyotypic pattern. The specific chromosomal changes viz., t(9;22), t(8;21), t(15;17), t/del(11q), 12p‐ were found in M1(3/5), M2(8/15), M3(8/8), M4(1/1) M5(2/4) and M2Ba(1/1) (M2 with Basophilia) patients. Abnormalities of 11q were also noted in two M2 patients showing monocytic involvement. A translocation involving chromosomes 6 and 9 was seen in one patient with M1 and two patients with M2. An inv(16) was observed in M1 (one case), M2 (two cases) and M6 (one case). A del(16) was noted in an M4 case. Although t(9;22) is frequently associated with M1 patients, it was also detected in M2 (two patients) and M4 (one patient). Among all the FAB specific anomalies described above, t(8;21) and t(15;17) were observed only in M2 and M3 patients, respectively. Interestingly, one M2 patient had two independent clones, one with t(8;21) and t(9;11). Deletion or translocation involving 11q was found in a Ph positive M4 patient. New structural rearrangements such as t(1;7) (q32;q36) in association with t(8;21), and t(14;22) (q32;q11) in association with del(11)(q23) were detected in a M2 and a M5 patient, respectively. In conclusion, our studies have revealed that the incidence of FAB specific abnormalities viz., t(8;21); t(15;17), t(9;22), t/del(11q) and also other recurrent anomalies viz., ‐7/7q‐, +8 is much higher in our patients, as compared with other countries. This difference may be attributed to the influence of differential environmental exposure to unknown carcinogenic agents.
The value of the immunological subtypes and individual markers compared to classical parameters in the prognosis of acute lymphoblastic leukemia
Authors: Gómez E. , Miguel J. F. San , González M. , Orfao A. , Cañizo M. C. , Moraleda J. M. , Borrasca A. López 
Published: February 2007

AbstractThe value of the immunophenotypical subtypes and individual markers was compared with classical parameters in the prognosis of 150 patients with acute lymphoblastic leukemia (ALL).Regarding the immunophenotype, common‐ALL had a better prognosis than T‐ALL in the children's group. However, in adults the situation was different since both null and T‐ALL patients had longer survival rates than the common/pre‐B group. Moreover, several individual markers add interesting prognostic information, either in ALL as a whole group or within the different immunophenotypes. Thus, the expression of CD 10 and TdT had a significantly favourable influence in the outcome of the whole series of patients; within the T‐ALL, those cases positive for CD10 also had a longer median survival (33 versus 17 months). In addition, in the common ALL patients group the expression of a relatively mature B marker—CD20—appeared to have a favourable prognosis (27 versus 13 months). Other non lineage specific markers, such as CD9 and CD38 did not seem to influence survival.Regarding the more conventional parameters, our data suggest that the classical age prognostic classification in children (> 15 years) and adults can be improved using two cut‐off points at 11 and 35 years. Moreover, the multivariate analysis showed that this variable, together with FAB morphology and WBC counts were the best combination of parameters for predicting survival.The present study shows that although the immunophenotype helps us in understanding the biological heterogeneity of ALL, having also prognostic implications, there are other clinical and hematological features that yield stronger prognostic information.
Short‐term remission induction and consolidation therapy for adult acute myelogenous leukemia
Authors: Battista R. , Bassan R. , D'Emilio A. , Dragone P. , Viero P. , Dini E. , Barbui T. 
Published: February 2007

AbstractOne hundred and ninety two adults (median age 44 years) withde novoor secondary (n= 17) acute myelogenous leukemia (AML) were managed with a maximum of six intended courses with adriamycin 25 mg/m2/d for three days, plus cytarabine 200 mg/m2/d and 6–thioguanine 200 mg/m2/d for seven days (short‐term therapy, STT). Twenty eight patients not in remission after the first course were given cytarabine 2 g/m2/bd for six days, a treatment that was highly toxic and gave a low CR rate. One hundred and twenty‐six patients overall (66 per cent) achieved a complete remission (CR), 117/164 (71 per cent) after one to three standard courses (median 1), and 9/28 (32 per cent) after high‐dose cytarabine. Median CR duration was 12 months. By multivariate analysis, younger age, blast count ≤ 50 × 109/L, andde novoAML were associated with a better outcome (p< 0.05). CR duration correlated favourably with FAB M3 morphology and total number (five or six) of cycles (p< 0.05). In patients receiving five or six total courses, median CR length resulted 15.5 months and leukemia‐free survival at 3 years 37 per cent. Therapy was curtailed in one fourth of CR patients because of unacceptable toxicity, and there were nine early deaths attributable to therapy‐related complications among 126 CR cases. STT may be a worthwhile form of treatment for patients withde novonon‐hyperleukocytic AML that are able to tolerate five or six consecutive induction‐like chemotherapy courses.
A simple, non‐invasive method of assessing the acute hemodynamic effects of doxorubicin
Authors: Clive Sally , Dawson Audrey , Bennett Bruce , Rawles John 
Published: February 2007

AbstractLeft ventricular stroke distance was measured by Doppler ultrasound in 10 doxorubicin‐treated and 10 control patients. Measurements were made 10 min, 2 h and 4 h after drug administration. Stroke distance (a linear analogue of stroke volume) increased significantly from 12.6 cm (S.D. 2.7) before and 12.5 cm (S.D. 2.7) 10 min after, to 13.6 cm (S.D. 2.8) 2 h after and 13.7 cm (S.D. 2.7) 4 h after doxorubicin (p < 0.05). Throughout the study period there were no significant changes in stroke distance in the control patients who were infused with similar fluid volumes, and no significant changes in heart rate or blood pressure in either group.These observations confirm previous findings made by radionuclide ventriculography, a much more complex, expensive and hazardous technique, not amenable to repetition at short time intervals. The measurement of stroke distance by Doppler ultrasound is a convenient bedside method of assessing acute hemodynamic changes after doxorubicin or any drug affecting cardiac function. The method we describe is eminently suitable for investigating the cardiotoxicity of chemotherapeutic agents.